First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder
Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with…
First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder
Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations. The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare…
AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation
If AI is not one of the CEO’s top two or three priorities, the organization will produce pilots and slide decks while better-mobilized peers pull ahead and the institution’s ability to fulfill its mission erodes The post AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation appeared first on MedCity…
Big Bucks, No Whammies: Patient Access Was Never the Finish Line
By STEPHEN FARBER If you grew up in the 1980s, you probably remember Press Your Luck. Contestants stood in front of a flashing game board chanting, “Big bucks… no Whammies… STOP!” hoping the next square held cash instead of the mischievous cartoon character that erased everything they had won. For years, assembling your own medical…
Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up
A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care. The post Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up appeared first on MedCity…
SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven
Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on…
The Missing Piece in Lowering the Cost of Care: Predictability
When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance. The post The Missing Piece in Lowering the Cost of Care: Predictability appeared first on MedCity News.
With Midterms Looming, Journalists Consider Measles, Food Recalls, and Obamacare
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed fatal measles cases on CBS News 24/7’s Mornings on Aug. 26. Gounder fact-checked Centers for Medicare & Medicaid Services Administrator Mehmet Oz’s comments about vaccines and drug prices on CBS News 24/7’s The Daily Report on Aug. 24. She also discussed food recalls this summer…
Epic MyChart Phishing Scam Hits Health Systems: What Providers Should Do
More than a dozen health systems are warning patients of a phishing campaign impersonating Epic’s MyChart portal with fake Medicare rewards and faux login pages. Experts say the scam exposes a deeper problem: patients can’t be expected to spot increasingly polished fakes, so the responsibility falls on providers to communicate in ways that build trust….
KFF Survey Methodology & Data Collection Standards
This publication describes KFF’s survey methodology and data collection standards, including how the polling team reaches survey respondents, works to be representative, and partners with other news organizations on its polling projects.
FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy
Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential. The post FDA Nod for Inflammation Drug Notches…
